Cargando…

Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis

OBJECTIVE: Non-alcoholic steatohepatitis (NASH) can progress to fibrosis, cirrhosis and end-stage liver disease. Glucagon-like peptide 1 receptor (GLP-1R) mediates β cell function. Its receptor agonists, currently used to treat type 2 diabetes mellitus, might be effective against NASH. GLP-1R, a G p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokomori, Hiroaki, Ando, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232783/ https://www.ncbi.nlm.nih.gov/pubmed/32414752 http://dx.doi.org/10.1136/bmjgast-2019-000370

Ejemplares similares

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
por: Armstrong, Matthew J., et al.
Publicado: (2016)

The Apelin Receptor APJ in Hematopoietic Stem Cells/Progenitor Cells in the Early Stage of Non-Alcoholic Steatohepatitis
por: Ando, Wataru, et al.
Publicado: (2017)

Systematic Evaluation of the Safety Threshold for Allograft Macrovesicular Steatosis in Cadaveric Liver Transplantation
por: Liu, Zhengtao, et al.
Publicado: (2019)

Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models
por: Wang, Xiao-Xiao, et al.
Publicado: (2023)

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients
por: Ferri, Flaminia, et al.
Publicado: (2019)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Computed Tomography-Based Radiomic Analysis for Preoperatively Predicting the Macrovesicular Steatosis Grade in Cadaveric Donor Liver Transplantation
por: Ding, Shengnan, et al.
Publicado: (2022)

CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis
por: Ju, Linling, et al.
Publicado: (2020)

Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis
por: Gunn, Pippa J., et al.
Publicado: (2020)

Impaired mitochondrial medium-chain fatty acid oxidation drives periportal macrovesicular steatosis in sirtuin-5 knockout mice
por: Goetzman, Eric S., et al.
Publicado: (2020)

Non-invasive real-time assessment of hepatic macrovesicular steatosis in liver donors: Hypothesis, design and proof-of-concept study
por: Rajamani, Allwyn S, et al.
Publicado: (2021)

Controlled attenuation parameter measured using transient elastography for the noninvasive assessment of macrovesicular steatosis in potential living liver donors
por: Lee, Sunyoung, et al.
Publicado: (2022)

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis
por: Ando, Wataru, et al.
Publicado: (2018)

Efficiency of Machine Learning Algorithms for the Determination of Macrovesicular Steatosis in Frozen Sections Stained with Sudan to Evaluate the Quality of the Graft in Liver Transplantation
por: Pérez-Sanz, Fernando, et al.
Publicado: (2021)

Knockdown of hepatocyte Perilipin-3 mitigates hepatic steatosis and steatohepatitis caused by hepatocyte CGI-58 deletion in mice
por: Bao, Xinyu, et al.
Publicado: (2022)

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
por: Barritt, A. Sidney, et al.
Publicado: (2022)

Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
por: Koh, Eun Hee, et al.
Publicado: (2021)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Survival of compromised adult sensory neurons involves macrovesicular formation
por: Krishnan, Anand, et al.
Publicado: (2022)

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
por: Xue, Huan, et al.
Publicado: (2023)

Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice
por: Wollman, Ayala, et al.
Publicado: (2019)

Steatosis and Steatohepatitis: Complex Disorders
por: Bettermann, Kira, et al.
Publicado: (2014)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
por: Lee, Won-Young
Publicado: (2017)

Molecular imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease by Raman microscopy
por: Minamikawa, Takeo, et al.
Publicado: (2020)

Hepatocyte caveolin-1 modulates metabolic gene profiles and functions in non-alcoholic fatty liver disease
por: Han, Mei, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
por: Kojima, Motoyasu, et al.
Publicado: (2020)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Caveolin-1 abrogates TGF-β mediated hepatocyte apoptosis
por: Meyer, C, et al.
Publicado: (2013)

Distinct dedifferentiation processes affect caveolin-1 expression in hepatocytes
por: Meyer, Christoph, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice
por: Nan, YueMin, et al.
Publicado: (2010)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease
por: Wang, Huan, et al.
Publicado: (2023)

Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes
por: Lyu, Jingya, et al.
Publicado: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Unexpected Findings of Regulatory Factor X6 Gene Mutation and Severe Hepatic Macrovesicular Steatosis in a Neonate with Congenital Left Ventricle Diverticulum: A Case Report
por: Edraki, Mohammad Reza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lq7djt2smt88lgnd3535n1i948